NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis $1.26 -0.02 (-1.56%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.01 (+1.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Geron Stock (NASDAQ:GERN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Geron alerts:Sign Up Key Stats Today's Range$1.25▼$1.3050-Day Range$1.23▼$1.6252-Week Range$1.17▼$4.89Volume6.75 million shsAverage Volume8.61 million shsMarket Capitalization$802.52 millionP/E RatioN/ADividend YieldN/APrice Target$4.61Consensus RatingModerate Buy Company Overview Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. Read More Geron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreGERN MarketRank™: Geron scored higher than 68% of companies evaluated by MarketBeat, and ranked 340th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageGeron has only been the subject of 2 research reports in the past 90 days.Read more about Geron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.68% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Geron has recently decreased by 3.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Sustainability and ESG1.3 / 5Environmental Score-2.75 Percentage of Shares Shorted10.68% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Geron has recently decreased by 3.43%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.42 News SentimentGeron has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Geron this week, compared to 12 articles on an average week.Search Interest16 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows14 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.42% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock News HeadlinesLeerink Partnrs Predicts Geron's Q4 Earnings (NASDAQ:GERN)July 25 at 4:43 AM | americanbankingnews.comCautiously Optimistic: Geron’s Strategic Changes and Growth Prospects Support Buy RatingJuly 21, 2025 | tipranks.comGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.July 25 at 2:00 AM | Stansberry Research (Ad)Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | gurufocus.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GERN Stock NewsJuly 18, 2025 | gurufocus.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | businesswire.comJohnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron ...July 18, 2025 | gurufocus.comGeron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program ProgressJuly 16, 2025 | msn.comSee More Headlines GERN Stock Analysis - Frequently Asked Questions How have GERN shares performed this year? Geron's stock was trading at $3.54 at the beginning of 2025. Since then, GERN shares have decreased by 64.4% and is now trading at $1.26. How were Geron's earnings last quarter? Geron Corporation (NASDAQ:GERN) released its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The company's revenue for the quarter was up 12927.3% on a year-over-year basis. Read the conference call transcript. Who are Geron's major shareholders? Geron's top institutional shareholders include Aberdeen Group plc (1.10%), Inspire Investing LLC (0.04%), Ballentine Partners LLC (0.01%) and 111 Capital (0.01%). Insiders that own company stock include Olivia Kyusuk Bloom, Scott Alan Samuels, John A Scarlett, Elizabeth G O'farrell, V Bryan Lawlis, Susan Molineaux, Faye Feller and Andrew J Grethlein. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings5/07/2025Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN Previous SymbolNASDAQ:GERN CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees229Year FoundedN/APrice Target and Rating Average Price Target for Geron$4.61 High Price Target$9.00 Low Price Target$1.00 Potential Upside/Downside+267.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$174.57 million Net Margins-119.54% Pretax Margin-119.54% Return on Equity-47.86% Return on Assets-26.78% Debt Debt-to-Equity Ratio0.44 Current Ratio7.87 Quick Ratio6.97 Sales & Book Value Annual Sales$76.99 million Price / Sales10.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book2.73Miscellaneous Outstanding Shares636,920,000Free Float589,659,000Market Cap$799.33 million OptionableOptionable Beta0.64 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:GERN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.